Neu erschienen von Mariacarla Gadebusch Bondio: “Cancer and the Life Beyond It”

Neu erschienen von Mariacarla Gadebusch Bondio: "Cancer and the Life Beyond It"

TP1 Leiterin Mariacarla Gadebusch Bondio und Ingo F. Herrmann, zusammen mit Maria Cristina Montani, veröffentlich ein Kapitel zum Thema “Cancer and the Life Beyond It. Patients Testimony as a Contribution to Subjective Evidence,” in: Axel W. Bauer, Ralf-Dieter Hofheinz, Jochen Sven Utikal (Hsg.) Ethical Challenges in Cancer Diagnosis and Therapy. Recent Results in Cancer Research, Vol. 218, 259-74. https://doi.org/10.1007/978-3-030-63749-1_17.

Abstract:

Patient narratives are a very valuable literary and medical resource. They transcribe the experience of illness into the life stories of the subject and the author. A serious case of cancer triggers the very individual experience of vulnerability, suffering, dependence, and even contingency in the no longer ‘open’ future. Even after overcoming cancer, life is never the same again. Writing about one’s own experience of cancer is a hermeneutic feat of strength with ethical and aesthetic implications. In the age of personalized and evidence-based medicine, patient narratives offer a particular and necessary supplement to the objectifying medical perspective, since they constitute expressions of subjective evidence. This article is based on the direct experience of cancer by the co-author of the narrative. The long history of her illness is presented chronologically in her own words and has been translated from Italian to English. This is followed by an essay, published here for the first time, on “the life beyond cancer”, on the patient’s time without tumors and the consequences of therapies and mutilating operations. Our methodological approach is based on Havi Carel’s Phenomenology of Illness. The close reading of this pathography focuses on three aspects: (1) the effect and power of words; (2) the passage from wariness to awareness; and (3) the maintenance of personal quality of life during and after cancer.